Status:
RECRUITING
Use of Physiology to Evaluate Procedural Result After PCI CTO
Lead Sponsor:
Isala
Collaborating Sponsors:
Abbott
Conditions:
Percutaneous Coronary Revascularisation
Complex Coronary Lesion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
ULTRA-CTO is a prospective multicentre non-randomised investigator-initiated trial designed to enrol 200 subjects with an indication for percutaneous coronary intervention (PCI) of chronic total occlu...
Detailed Description
ULTRA-CTO is a prospective multicentre non-randomised investigator-initiated trial designed to enrol 200 subjects with an indication for PCI CTO. The main objective of the study is to evaluate both t...
Eligibility Criteria
Inclusion
- Age 18 years and older.
- Angiographically successful PCI CTO without any remaining lesion at least 30% proximal to the stented segment.
- Possibility to perform physiologic measurements and OCT of sufficient quality.
- Patients willing and capable to provide written informed consent.
Exclusion
- 1\) Contra-indication for adenosine.
Key Trial Info
Start Date :
July 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04780971
Start Date
July 21 2021
End Date
June 1 2026
Last Update
February 19 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud UMC
Nijmegen, Netherlands
2
Isala
Zwolle, Netherlands, 8025 AB